Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Corn

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Clinical Nuclear Medicine|November 6, 2020
Incidental Detection of Urothelial Carcinoma on 18F-Fluciclovine PET/CTDevaki Shilpa Sudha Surasi, Yang Lu, Paul Corn, et al.
Leukemia Research|September 8, 2009
5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosisBenigno C Valdez, Yang Li, David Murray, et al.
The Journal of Urology|September 11, 2013
Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedulesBradley J Atkinson, Sarathi Kalra, Xuemei Wang, et al.
Leukemia & Lymphoma|October 23, 2013
The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfanGuiyun Song, Benigno C Valdez, Yang Li, et al.
BJU International|September 24, 2013
Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomesBradley J Atkinson, Diana H Cauley, Chaan Ng, et al.
Cancers|January 23, 2020
Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate CancerFilippos Koinis, Paul Corn, Nila Parikh, et al.
Cancer Biology & Therapy|October 27, 2009
Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formationJohn C Araujo, Ann Poblenz, Paul Corn, et al.
European Urology Oncology|August 15, 2019
Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer PatientsEleni Efstathiou, Mark Titus, Sijin Wen, et al.
BJU International|November 18, 2015
Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experienceMarc R Matrana, Tharakeswara Bathala, Matthew T Campbell, et al.
Research Square|November 1, 2024
Polyploid cancer cells reveal signatures of chemotherapy resistanceJames Hicks, Michael Schmidt, Amin Nahgdloo, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Clinical Nuclear Medicine|November 6, 2020
Incidental Detection of Urothelial Carcinoma on 18F-Fluciclovine PET/CTDevaki Shilpa Sudha Surasi, Yang Lu, Paul Corn, et al.
Leukemia Research|September 8, 2009
5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosisBenigno C Valdez, Yang Li, David Murray, et al.
The Journal of Urology|September 11, 2013
Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedulesBradley J Atkinson, Sarathi Kalra, Xuemei Wang, et al.
Leukemia & Lymphoma|October 23, 2013
The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfanGuiyun Song, Benigno C Valdez, Yang Li, et al.
BJU International|September 24, 2013
Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomesBradley J Atkinson, Diana H Cauley, Chaan Ng, et al.
Cancers|January 23, 2020
Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate CancerFilippos Koinis, Paul Corn, Nila Parikh, et al.
Cancer Biology & Therapy|October 27, 2009
Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formationJohn C Araujo, Ann Poblenz, Paul Corn, et al.
European Urology Oncology|August 15, 2019
Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer PatientsEleni Efstathiou, Mark Titus, Sijin Wen, et al.
BJU International|November 18, 2015
Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experienceMarc R Matrana, Tharakeswara Bathala, Matthew T Campbell, et al.
Research Square|November 1, 2024
Polyploid cancer cells reveal signatures of chemotherapy resistanceJames Hicks, Michael Schmidt, Amin Nahgdloo, et al.
Pageof 4